Zenas BioPharma, Inc. (NASDAQ: ZBIO) Stock Competitors & Peer Comparison
See ZBIO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ZBIO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZBIO | $31.50 | -1.47% | 2B | -3.50 | -$8.99 | N/A |
| VRTX | $508.34 | -1.55% | 129B | 26.70 | $19.03 | N/A |
| REGN | $784.85 | -0.58% | 80.9B | 17.20 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $990.32 | -0.55% | 61.6B | 89.38 | $11.08 | N/A |
| MRNA | $154.04 | -2.55% | 61.1B | -18.90 | -$8.15 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $190.95 | -3.04% | 40.6B | -21.64 | -$8.82 | N/A |
| RVMDW | $9.64 | -6.36% | 38.3B | -1.11 | -$8.82 | N/A |
| ONC | $350.84 | -0.74% | 37.5B | 61.77 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ZBIO vs VRTX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, VRTX has a market cap of 129B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while VRTX trades at $508.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas VRTX's P/E ratio is 26.70. In terms of profitability, ZBIO's ROE is -1.90%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ZBIO is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ZBIO vs REGN Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, REGN has a market cap of 80.9B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while REGN trades at $784.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas REGN's P/E ratio is 17.20. In terms of profitability, ZBIO's ROE is -1.90%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ZBIO is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
ZBIO vs VRNA Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ZBIO's ROE is -1.90%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ZBIO is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
ZBIO vs ARGX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ARGX has a market cap of 61.6B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ARGX trades at $990.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ARGX's P/E ratio is 89.38. In terms of profitability, ZBIO's ROE is -1.90%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, ZBIO is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
ZBIO vs MRNA Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, MRNA has a market cap of 61.1B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while MRNA trades at $154.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas MRNA's P/E ratio is -18.90. In terms of profitability, ZBIO's ROE is -1.90%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ZBIO is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check MRNA's competition here
Seagen Inc. (NASDAQ: SGEN)
ZBIO vs SGEN Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ZBIO's ROE is -1.90%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ZBIO is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ZBIO vs RVMD Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, RVMD has a market cap of 40.6B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while RVMD trades at $190.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas RVMD's P/E ratio is -21.64. In terms of profitability, ZBIO's ROE is -1.90%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ZBIO is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ZBIO vs RVMDW Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, RVMDW has a market cap of 38.3B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while RVMDW trades at $9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas RVMDW's P/E ratio is -1.11. In terms of profitability, ZBIO's ROE is -1.90%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ZBIO is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check RVMDW's competition here
BeOne Medicines AG (NASDAQ: ONC)
ZBIO vs ONC Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ONC has a market cap of 37.5B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ONC trades at $350.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ONC's P/E ratio is 61.77. In terms of profitability, ZBIO's ROE is -1.90%, compared to ONC's ROE of +0.14%. Regarding short-term risk, ZBIO is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ZBIO vs ALNY Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ALNY has a market cap of 32.9B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ALNY trades at $239.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ALNY's P/E ratio is 44.24. In terms of profitability, ZBIO's ROE is -1.90%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ZBIO is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ZBIO vs ROIV Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ROIV has a market cap of 28.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ROIV trades at $39.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ROIV's P/E ratio is -37.84. In terms of profitability, ZBIO's ROE is -1.90%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ZBIO is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
ZBIO vs INSM Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, INSM has a market cap of 26B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while INSM trades at $120.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas INSM's P/E ratio is -29.20. In terms of profitability, ZBIO's ROE is -1.90%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ZBIO is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
ZBIO vs INCY Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, INCY has a market cap of 25.4B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while INCY trades at $125.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas INCY's P/E ratio is 16.84. In terms of profitability, ZBIO's ROE is -1.90%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ZBIO is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
ZBIO vs BNTX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, BNTX has a market cap of 24.1B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while BNTX trades at $96.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas BNTX's P/E ratio is -12.46. In terms of profitability, ZBIO's ROE is -1.90%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ZBIO is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check BNTX's competition here
Genmab A/S (NASDAQ: GMAB)
ZBIO vs GMAB Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while GMAB trades at $34.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas GMAB's P/E ratio is 26.18. In terms of profitability, ZBIO's ROE is -1.90%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ZBIO is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check GMAB's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ZBIO vs UTHR Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, UTHR has a market cap of 21B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while UTHR trades at $494.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas UTHR's P/E ratio is 17.70. In terms of profitability, ZBIO's ROE is -1.90%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ZBIO is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ZBIO vs BGNE Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ZBIO's ROE is -1.90%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ZBIO is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ZBIO vs DNA-WT Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ZBIO's ROE is -1.90%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ZBIO is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ZBIO vs JAZZ Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while JAZZ trades at $240.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas JAZZ's P/E ratio is 8.98. In terms of profitability, ZBIO's ROE is -1.90%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ZBIO is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ZBIO vs NBIX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, NBIX has a market cap of 14.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while NBIX trades at $146.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas NBIX's P/E ratio is 21.13. In terms of profitability, ZBIO's ROE is -1.90%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ZBIO is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ZBIO vs ASND Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ASND trades at $236.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ASND's P/E ratio is -97.82. In terms of profitability, ZBIO's ROE is -1.90%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ZBIO is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ZBIO vs EXEL Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while EXEL trades at $58.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas EXEL's P/E ratio is 16.67. In terms of profitability, ZBIO's ROE is -1.90%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ZBIO is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ZBIO vs SMMT Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, SMMT has a market cap of 14.2B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while SMMT trades at $17.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas SMMT's P/E ratio is -15.94. In terms of profitability, ZBIO's ROE is -1.90%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ZBIO is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ZBIO vs HALO Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, HALO has a market cap of 13.3B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while HALO trades at $112.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas HALO's P/E ratio is 20.98. In terms of profitability, ZBIO's ROE is -1.90%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ZBIO is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ZBIO vs BBIO Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while BBIO trades at $66.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas BBIO's P/E ratio is -17.81. In terms of profitability, ZBIO's ROE is -1.90%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ZBIO is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ZBIO vs KRTX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ZBIO's ROE is -1.90%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ZBIO is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ZBIO vs BMRN Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while BMRN trades at $63.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas BMRN's P/E ratio is 30.74. In terms of profitability, ZBIO's ROE is -1.90%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ZBIO is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ZBIO vs MDGL Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, MDGL has a market cap of 12.3B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while MDGL trades at $531.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas MDGL's P/E ratio is -41.52. In terms of profitability, ZBIO's ROE is -1.90%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ZBIO is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ZBIO vs TECH Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while TECH trades at $72.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas TECH's P/E ratio is 37.30. In terms of profitability, ZBIO's ROE is -1.90%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ZBIO is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ZBIO vs RNAM Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ZBIO's ROE is -1.90%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ZBIO is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ZBIO vs AXSM Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, AXSM has a market cap of 10.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while AXSM trades at $207.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas AXSM's P/E ratio is -54.25. In terms of profitability, ZBIO's ROE is -1.90%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ZBIO is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check AXSM's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
ZBIO vs TWST Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, TWST has a market cap of 10.4B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while TWST trades at $166.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas TWST's P/E ratio is -75.22. In terms of profitability, ZBIO's ROE is -1.90%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ZBIO is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check TWST's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ZBIO vs KRYS Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while KRYS trades at $336.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas KRYS's P/E ratio is 42.19. In terms of profitability, ZBIO's ROE is -1.90%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ZBIO is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check KRYS's competition here
10x Genomics, Inc. (NASDAQ: TXG)
ZBIO vs TXG Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, TXG has a market cap of 9.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while TXG trades at $76.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas TXG's P/E ratio is -129.83. In terms of profitability, ZBIO's ROE is -1.90%, compared to TXG's ROE of -0.09%. Regarding short-term risk, ZBIO is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check TXG's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ZBIO vs KYMR Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while KYMR trades at $117.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas KYMR's P/E ratio is -36.80. In terms of profitability, ZBIO's ROE is -1.90%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ZBIO is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check KYMR's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ZBIO vs RXDX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ZBIO's ROE is -1.90%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ZBIO is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check RXDX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ZBIO vs ARWR Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ARWR has a market cap of 9.4B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ARWR trades at $66.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ARWR's P/E ratio is -29.55. In terms of profitability, ZBIO's ROE is -1.90%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ZBIO is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check ARWR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ZBIO vs PTGX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, PTGX has a market cap of 9.2B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while PTGX trades at $143.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas PTGX's P/E ratio is 138.83. In terms of profitability, ZBIO's ROE is -1.90%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ZBIO is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ZBIO vs NUVL Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ZBIO's ROE is -1.90%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ZBIO is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ZBIO vs CRNX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ZBIO's ROE is -1.90%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ZBIO is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check CRNX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ZBIO vs IBRX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while IBRX trades at $8.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas IBRX's P/E ratio is -8.74. In terms of profitability, ZBIO's ROE is -1.90%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ZBIO is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check IBRX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ZBIO vs IMGN Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ZBIO's ROE is -1.90%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ZBIO is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ZBIO vs TGTX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, TGTX has a market cap of 8.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while TGTX trades at $56.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas TGTX's P/E ratio is 20.61. In terms of profitability, ZBIO's ROE is -1.90%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ZBIO is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check TGTX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ZBIO vs CYTK Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, CYTK has a market cap of 8.6B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while CYTK trades at $68.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas CYTK's P/E ratio is -9.53. In terms of profitability, ZBIO's ROE is -1.90%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ZBIO is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check CYTK's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ZBIO vs CAI Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, CAI has a market cap of 8.5B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while CAI trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas CAI's P/E ratio is 84.24. In terms of profitability, ZBIO's ROE is -1.90%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ZBIO is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check CAI's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ZBIO vs PCVX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while PCVX trades at $58.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas PCVX's P/E ratio is -7.62. In terms of profitability, ZBIO's ROE is -1.90%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ZBIO is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ZBIO vs BPMC Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ZBIO's ROE is -1.90%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ZBIO is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ZBIO vs APGE Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas APGE's P/E ratio is -31.19. In terms of profitability, ZBIO's ROE is -1.90%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ZBIO is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check APGE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ZBIO vs PRAX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, PRAX has a market cap of 8.3B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while PRAX trades at $298.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas PRAX's P/E ratio is -23.12. In terms of profitability, ZBIO's ROE is -1.90%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ZBIO is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ZBIO vs CERE Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas CERE's P/E ratio is -16.47. In terms of profitability, ZBIO's ROE is -1.90%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ZBIO is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check CERE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ZBIO vs SYRE Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, SYRE has a market cap of 7.8B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while SYRE trades at $90.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas SYRE's P/E ratio is -46.28. In terms of profitability, ZBIO's ROE is -1.90%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ZBIO is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check SYRE's competition here
Abivax S.A. (NASDAQ: ABVX)
ZBIO vs ABVX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ABVX has a market cap of 7.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ABVX trades at $105.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ABVX's P/E ratio is -55.06. In terms of profitability, ZBIO's ROE is -1.90%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ZBIO is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check ABVX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ZBIO vs IMVT Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, IMVT has a market cap of 7.6B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while IMVT trades at $36.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas IMVT's P/E ratio is -13.10. In terms of profitability, ZBIO's ROE is -1.90%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ZBIO is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check IMVT's competition here
Metsera, Inc. (NASDAQ: MTSR)
ZBIO vs MTSR Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ZBIO's ROE is -1.90%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ZBIO is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ZBIO vs IONS Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, IONS has a market cap of 7.4B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while IONS trades at $44.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas IONS's P/E ratio is -25.84. In terms of profitability, ZBIO's ROE is -1.90%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ZBIO is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check IONS's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ZBIO vs BLTE Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, BLTE has a market cap of 6.9B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while BLTE trades at $170.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas BLTE's P/E ratio is -91.42. In terms of profitability, ZBIO's ROE is -1.90%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ZBIO is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check BLTE's competition here
Merus N.V. (NASDAQ: MRUS)
ZBIO vs MRUS Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ZBIO's ROE is -1.90%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ZBIO is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ZBIO vs ACLX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ZBIO's ROE is -1.90%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ZBIO is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check ACLX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ZBIO vs RYTM Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, RYTM has a market cap of 6.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while RYTM trades at $97.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas RYTM's P/E ratio is -31.42. In terms of profitability, ZBIO's ROE is -1.90%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ZBIO is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check RYTM's competition here
CG Oncology Inc. (NASDAQ: CGON)
ZBIO vs CGON Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while CGON trades at $74.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas CGON's P/E ratio is -27.74. In terms of profitability, ZBIO's ROE is -1.90%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ZBIO is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ZBIO vs RETA Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas RETA's P/E ratio is -66.29. In terms of profitability, ZBIO's ROE is -1.90%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ZBIO is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ZBIO vs CNTA Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ZBIO's ROE is -1.90%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ZBIO is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ZBIO vs TVTX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while TVTX trades at $62.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas TVTX's P/E ratio is -139.47. In terms of profitability, ZBIO's ROE is -1.90%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ZBIO is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check TVTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ZBIO vs ORKA Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ORKA has a market cap of 5.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ORKA trades at $94.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ORKA's P/E ratio is -48.95. In terms of profitability, ZBIO's ROE is -1.90%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ZBIO is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check ORKA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ZBIO vs LGND Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while LGND trades at $283.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas LGND's P/E ratio is 31.12. In terms of profitability, ZBIO's ROE is -1.90%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ZBIO is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ZBIO vs CDTX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ZBIO's ROE is -1.90%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ZBIO is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check CDTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ZBIO vs MIRM Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while MIRM trades at $91.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas MIRM's P/E ratio is -6.31. In terms of profitability, ZBIO's ROE is -1.90%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ZBIO is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check MIRM's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ZBIO vs SRRK Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while SRRK trades at $46.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas SRRK's P/E ratio is -13.52. In terms of profitability, ZBIO's ROE is -1.90%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ZBIO is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check SRRK's competition here
Abcam plc (NASDAQ: ABCM)
ZBIO vs ABCM Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ZBIO's ROE is -1.90%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ZBIO is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ZBIO vs ISEE Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ZBIO's ROE is -1.90%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ZBIO is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check ISEE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ZBIO vs PTCT Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while PTCT trades at $65.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas PTCT's P/E ratio is -28.06. In terms of profitability, ZBIO's ROE is -1.90%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ZBIO is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check PTCT's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ZBIO vs CRSP Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while CRSP trades at $56.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas CRSP's P/E ratio is -11.88. In terms of profitability, ZBIO's ROE is -1.90%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ZBIO is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check CRSP's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ZBIO vs DNTH Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, DNTH has a market cap of 5.4B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while DNTH trades at $96.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas DNTH's P/E ratio is -23.33. In terms of profitability, ZBIO's ROE is -1.90%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ZBIO is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ZBIO vs COGT Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while COGT trades at $31.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas COGT's P/E ratio is -14.93. In terms of profitability, ZBIO's ROE is -1.90%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ZBIO is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check COGT's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ZBIO vs APLS Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas APLS's P/E ratio is 38.35. In terms of profitability, ZBIO's ROE is -1.90%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ZBIO is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ZBIO vs DFTX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while DFTX trades at $38.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas DFTX's P/E ratio is N/A. In terms of profitability, ZBIO's ROE is -1.90%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ZBIO is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check DFTX's competition here
Erasca, Inc. (NASDAQ: ERAS)
ZBIO vs ERAS Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ERAS trades at $14.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ERAS's P/E ratio is -15.88. In terms of profitability, ZBIO's ROE is -1.90%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ZBIO is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check ERAS's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ZBIO vs EWTX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while EWTX trades at $45.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas EWTX's P/E ratio is -24.50. In terms of profitability, ZBIO's ROE is -1.90%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ZBIO is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check EWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
ZBIO vs PBLS Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, PBLS has a market cap of 4.9B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while PBLS trades at $41.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas PBLS's P/E ratio is -47.42. In terms of profitability, ZBIO's ROE is -1.90%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, ZBIO is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check PBLS's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ZBIO vs TERN Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas TERN's P/E ratio is -51.41. In terms of profitability, ZBIO's ROE is -1.90%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ZBIO is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
ZBIO vs ACAD Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ACAD has a market cap of 4.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ACAD trades at $27.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ACAD's P/E ratio is 12.29. In terms of profitability, ZBIO's ROE is -1.90%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, ZBIO is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check ACAD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
ZBIO vs IOVA Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, IOVA has a market cap of 4.6B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while IOVA trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas IOVA's P/E ratio is -14.04. In terms of profitability, ZBIO's ROE is -1.90%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, ZBIO is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check IOVA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ZBIO vs ADPT Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ADPT has a market cap of 4.6B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ADPT trades at $28.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ADPT's P/E ratio is -69.63. In terms of profitability, ZBIO's ROE is -1.90%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ZBIO is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ZBIO vs FOLD Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ZBIO's ROE is -1.90%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ZBIO is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ZBIO vs AKRO Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ZBIO's ROE is -1.90%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ZBIO is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ZBIO vs ALPN Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ZBIO's ROE is -1.90%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ZBIO is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check ALPN's competition here
Veradermics, Incorporated (NYSE: MANE)
ZBIO vs MANE Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while MANE trades at $106.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas MANE's P/E ratio is -33.96. In terms of profitability, ZBIO's ROE is -1.90%, compared to MANE's ROE of -0.38%. Regarding short-term risk, ZBIO is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check MANE's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
ZBIO vs TLX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, TLX has a market cap of 4.3B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while TLX trades at $12.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas TLX's P/E ratio is 131.42. In terms of profitability, ZBIO's ROE is -1.90%, compared to TLX's ROE of +0.07%. Regarding short-term risk, ZBIO is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check TLX's competition here
Opthea Limited (NASDAQ: OPT)
ZBIO vs OPT Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas OPT's P/E ratio is -1.52. In terms of profitability, ZBIO's ROE is -1.90%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ZBIO is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ZBIO vs PRTC Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ZBIO's ROE is -1.90%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ZBIO is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check PRTC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ZBIO vs RLAY Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while RLAY trades at $18.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas RLAY's P/E ratio is -12.00. In terms of profitability, ZBIO's ROE is -1.90%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ZBIO is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ZBIO vs MRTX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ZBIO's ROE is -1.90%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ZBIO is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
ZBIO vs CELC Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, CELC has a market cap of 3.9B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while CELC trades at $80.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas CELC's P/E ratio is -18.75. In terms of profitability, ZBIO's ROE is -1.90%, compared to CELC's ROE of -3.51%. Regarding short-term risk, ZBIO is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check CELC's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
ZBIO vs ABCL Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while ABCL trades at $12.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas ABCL's P/E ratio is -23.39. In terms of profitability, ZBIO's ROE is -1.90%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, ZBIO is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ZBIO vs CPRX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ZBIO's ROE is -1.90%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ZBIO is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check CPRX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ZBIO vs XENE Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while XENE trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas XENE's P/E ratio is -8.46. In terms of profitability, ZBIO's ROE is -1.90%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ZBIO is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check XENE's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
ZBIO vs AMLX Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, AMLX has a market cap of 3.8B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while AMLX trades at $32.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas AMLX's P/E ratio is -22.63. In terms of profitability, ZBIO's ROE is -1.90%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, ZBIO is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for ZBIO.Check AMLX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ZBIO vs RYZB Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ZBIO's ROE is -1.90%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ZBIO is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ZBIO vs CBAY Comparison September 2026
Zenas BioPharma, Inc. (NASDAQ: ZBIO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZBIO stands at 2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ZBIO is priced at $31.50 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZBIO currently has a P/E ratio of -3.50, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ZBIO's ROE is -1.90%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ZBIO is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ZBIO.Check CBAY's competition here